East Greenwich woman takes ALS fight to national stage
EAST GREENWICH The Thompsons have had an unwanted visitor living in their home since late 2018, a cruel presence that goes by amyotrophic lateral sclerosis, or ALS.
It began for the family Aug. 31, 2018, when Olin Thompson, then a 47-year-old federal public defender and highly regarded contender for the Superior Court bench, had trouble lifting his right foot.
By that December, they had a diagnosis. It was ALS, commonly known as Lou Gehrig’s disease.
“It’s a diagnosis of exclusion. People are praying for anything other than ALS,” said Christa Thompson, who met Olin when the two went to Camp Fuller in Wakefield as kids. Today, they have three sons, Olin IV, Atticus and Nathaniel, ages 18, 14, and 11.
COVID-19 in Illinois updates: Here s what s happening this weekend
chicagotribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagotribune.com Daily Mail and Mail on Sunday newspapers.
Ex-Obama staffer says COVID-19 vaccines show ALS cure is possible
chicagotribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagotribune.com Daily Mail and Mail on Sunday newspapers.
Share:
NEW YORK, Dec. 14, 2020 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the Company s recently concluded pivotal Phase 3 clinical trial and meet specific eligibility requirements.
The protocol for the EAP was developed in partnership with the United States Food and Drug Administration (FDA) to provide access to NurOwn for Phase 3 clinical trial participants who meet specific eligibility criteria. Initially, patients less severely affected by ALS, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R), will be the first to receive treatment. This approach is informed by recently announced topline data from the Company s Phase 3 clinical trial. According to the